Beckmann S, Denhaerynck K, Stampf S, Saigi-Morgui N, Binet I, Koller M, Boely E, De Geest S, Psychosocial Interest Group 2018, Swiss Transplant Cohort Study. New-onset obesity after liver transplantation-outcomes and risk factors: the Swiss Transplant Cohort Study. Transpl Int. 2018 Nov;31(11):1254-67. doi: 10.1111/tri.13308
Rodrigo-Claverol M, Malla-Clua B, Rodrigo-Claverol E, Jove-Naval J, Bergada-Bell-Iloc J, Marsal-Mora JR. Animal-assisted therapy for the emotional well-being of children with intellectual disabilities and behavioral disorders. Sociology and Anthropology. 2018 Jan;6(1):94-106. doi: 10.13189/sa.2018.060109
Hirsch IB, Xu Y, Davis KL, Calingaert B. Patient factors associated with glucagonlike peptide 1 receptor agonist use with and without insulin. Endocr Pract. 2011 Sep 1;17(5):707-16.
Davis KL, Candrilli SD, Edin HM. Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population. Epilepsia. 2008 Mar 1;49(3):446-54.
Huerta C, Rivero E, Rodriguez LA. Incidence and risk factors for psoriasis in the general population. Arch Dermatol. 2007 Dec;143(12):1559-65.
McAfee AT, Chilcott KE, Johannes CB, Hornbuckle K, Hauser WA, Walker AM. The incidence of first provoked and unprovoked seizure in pediatric patients with and without psychiatric diagnoses. Epilepsia. 2007 Jun 1;48(6):1075-82.
Tunceli K, Pladevall-Vila M, Williams LK, Divine GW, Simpkins JC, Nag SS, Sajjan SG, Kamal-Bahl SJ, Alexander CM, Lafata JE. Trends in lipid management among patients with diabetes. Endocr Pract. 2006 Jul;12(4):380-7.
Arana A. A North American Registry for epilepsy and pregnancy, a unique public/private partnership of health surveillance. Epilepsia. 1998 Jul;39(7):793-8.
Dalla Bernardina B, Fontana E, Vigevano F, Fusco L, Torelli D, Galeone D, Buti D, Ciancheti C, Gnanasakthy A, Iudice A. Efficacy and tolerability of vigabatrin in children with refractory partial seizures: a single-blind dose-increasing study. Epilepsia. 1995 Jul;36(7):687-91.